Department of Bioengineering, Stanford University, Stanford, California, United States of America.
PLoS One. 2013;8(4):e60498. doi: 10.1371/journal.pone.0060498. Epub 2013 Apr 3.
Cystine-knot miniproteins, also known as knottins, have shown great potential as molecular scaffolds for the development of targeted therapeutics and diagnostic agents. For this purpose, previous protein engineering efforts have focused on knottins based on the Ecballium elaterium trypsin inhibitor (EETI) from squash seeds, the Agouti-related protein (AgRP) neuropeptide from mammals, or the Kalata B1 uterotonic peptide from plants. Here, we demonstrate that Agatoxin (AgTx), an ion channel inhibitor found in spider venom, can be used as a molecular scaffold to engineer knottins that bind with high-affinity to a tumor-associated integrin receptor.
METHODOLOGY/PRINCIPAL FINDINGS: We used a rational loop-grafting approach to engineer AgTx variants that bound to αvβ3 integrin with affinities in the low nM range. We showed that a disulfide-constrained loop from AgRP, a structurally-related knottin, can be substituted into AgTx to confer its high affinity binding properties. In parallel, we identified amino acid mutations required for efficient in vitro folding of engineered integrin-binding AgTx variants. Molecular imaging was used to evaluate in vivo tumor targeting and biodistribution of an engineered AgTx knottin compared to integrin-binding knottins based on AgRP and EETI. Knottin peptides were chemically synthesized and conjugated to a near-infrared fluorescent dye. Integrin-binding AgTx, AgRP, and EETI knottins all generated high tumor imaging contrast in U87MG glioblastoma xenograft models. Interestingly, EETI-based knottins generated significantly lower non-specific kidney imaging signals compared to AgTx and AgRP-based knottins.
CONCLUSIONS/SIGNIFICANCE: In this study, we demonstrate that AgTx, a knottin from spider venom, can be engineered to bind with high affinity to a tumor-associated receptor target. This work validates AgTx as a viable molecular scaffold for protein engineering, and further demonstrates the promise of using tumor-targeting knottins as probes for in vivo molecular imaging.
胱氨酸环微蛋白,也称为环肽,在作为靶向治疗和诊断试剂的分子支架方面显示出巨大的潜力。为此,以前的蛋白质工程工作集中在基于葫芦科植物( squash )胰蛋白酶抑制剂(EETI)、哺乳动物中的 Agouti 相关蛋白(AgRP)神经肽或植物中的 Kalata B1 子宫收缩肽的环肽。在这里,我们证明蜘蛛毒液中的离子通道抑制剂 Agatoxin(AgTx)可用作分子支架来设计以高亲和力结合肿瘤相关整合素受体的环肽。
方法/主要发现:我们使用合理的环嫁接方法来设计与 αvβ3 整合素结合的 AgTx 变体,亲和力在低 nM 范围内。我们表明,结构相关的环肽 AgRP 的一个二硫键约束环可以取代 AgTx 来赋予其高亲和力结合特性。同时,我们确定了工程化结合整合素的 AgTx 变体进行有效体外折叠所需的氨基酸突变。分子成像用于评估与基于 AgRP 和 EETI 的整合素结合环肽相比,工程化 AgTx 环肽在体内肿瘤靶向和生物分布中的作用。环肽通过化学合成并与近红外荧光染料缀合。AgTx、AgRP 和 EETI 环肽在 U87MG 胶质母细胞瘤异种移植模型中均产生了高肿瘤成像对比度。有趣的是,与基于 AgTx 和 AgRP 的环肽相比,EETI 基环肽产生的非特异性肾脏成像信号明显更低。
结论/意义:在这项研究中,我们证明了 AgTx,一种来自蜘蛛毒液的环肽,可以被设计以高亲和力结合肿瘤相关受体靶标。这项工作验证了 AgTx 作为蛋白质工程可行的分子支架,并进一步证明了使用肿瘤靶向环肽作为体内分子成像探针的潜力。